Real-time multi-spectral imaging for accurate detection of cancerous tissue in e...
Real-time multi-spectral imaging for accurate detection of cancerous tissue in endoscopic surgery
Cancer is the leading cause of death in the EU, with 2.7M diagnoses and 1.3M deaths in 2020. Effective removal of cancerous tissue through endoscopic surgery is challenging because of limited visual and absent tactile information,...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
RTC-2016-5702-1
Desarrollo y homologación de equipo clínico compacto de reso...
475K€
Cerrado
RTC-2015-3287-1
Desarrollo de un algoritmo diagnóstico multimodal incluyendo...
193K€
Cerrado
TAcTIC
TArgeTed molecular Imaging and surgery for gastro intestinal...
150K€
Cerrado
MONOBREAST
Low-dose breast CT with monochromatic x-ray sources
150K€
Cerrado
DPI2008-06691
TECNICAS PARA LA FUSION DE IMAGENES MR Y PET PARA LA LOCALIZ...
47K€
Cerrado
BIO2008-06843-C04-01
AISLAMIENTO NO INVASIVO DE CELULAS TUMORALES CIRCULANTES EN...
121K€
Cerrado
Información proyecto rMSI
Duración del proyecto: 23 meses
Fecha Inicio: 2022-10-24
Fecha Fin: 2024-09-30
Líder del proyecto
THERICON GMBH
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
4M€
Descripción del proyecto
Cancer is the leading cause of death in the EU, with 2.7M diagnoses and 1.3M deaths in 2020. Effective removal of cancerous tissue through endoscopic surgery is challenging because of limited visual and absent tactile information, along the limitations of current imaging technologies, which make it difficult for surgeons to differentiate between different types of tissue. For this market, Thericon is developing an rMSI (real-time multispectral imaging) platform providing surgeons with multi-parametric images that help with effective removal of cancerous tissue and reduction of cancer recurrence in patients. The company has developed a prototype for its first product, named rMSI 2, and completed initial validation for bladder cancer applications. Thericon is asking for a 2.5M EIC grant and 5.5M equity funding to complete clinical application pilots, safety tests and CE certification for this product, getting it ready for market launch in 2024.